Literature DB >> 17598142

Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity.

Jared R Auclair1, Karin M Green, Shivender Shandilya, James E Evans, Mohan Somasundaran, Celia A Schiffer.   

Abstract

HIV-1 Vif, an accessory protein in the viral genome, performs an important role in viral pathogenesis by facilitating the degradation of APOBEC3G, an endogenous cellular inhibitor of HIV-1 replication. In this study, intrinsically disordered regions are predicted in HIV-1 Vif using sequence-based algorithms. Intrinsic disorder may explain why traditional structure determination of HIV-1 Vif has been elusive, making structure-based drug design impossible. To characterize HIV-1 Vif's structural topology and to map the domains involved in oligomerization we used chemical cross-linking, proteolysis, and mass spectrometry. Cross-linking showed evidence of monomer, dimer, and trimer species via denaturing gel analysis and an additional tetramer via western blot analysis. We identified 47 unique linear peptides and 24 (13 intramolecular; 11 intermolecular) noncontiguous, cross-linked peptides, among the noncross-linked monomer, cross-linked monomer, cross-linked dimer, and cross-linked trimer samples. Almost complete peptide coverage of the N-terminus is observed in all samples analyzed, however reduced peptide coverage in the C-terminal region is observed in the dimer and trimer samples. These differences in peptide coverage or "protections" between dimer and trimer indicate specific differences in packing between the two oligomeric forms. Intramolecular cross-links within the monomer suggest that the N-terminus is likely folded into a compact domain, while the C-terminus remains intrinsically disordered. Upon oligomerization, as evidenced by the intermolecular cross-links, the C-terminus of one Vif protein becomes ordered by wrapping back on the N-terminal domain of another. In addition, the majority of the intramolecular cross-links map to regions that have been previously reported to be necessary for viral infectivity. Thus, this data suggests HIV-1 Vif is in a dynamic equilibrium between the various oligomers potentially allowing it to interact with other binding partners. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17598142      PMCID: PMC3366188          DOI: 10.1002/prot.21471

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  58 in total

1.  Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: co-encapsidation and interference with viral protease-mediated Gag processing.

Authors:  Martine Bardy; Bernard Gay; Stéphanie Pébernard; Nathalie Chazal; Marianne Courcoul; Robert Vigne; Etienne Decroly; Pierre Boulanger
Journal:  J Gen Virol       Date:  2001-11       Impact factor: 3.891

2.  Sequence complexity of disordered protein.

Authors:  P Romero; Z Obradovic; X Li; E C Garner; C J Brown; A K Dunker
Journal:  Proteins       Date:  2001-01-01

3.  Proteolytic 18O labeling for comparative proteomics: model studies with two serotypes of adenovirus.

Authors:  X Yao; A Freas; J Ramirez; P A Demirev; C Fenselau
Journal:  Anal Chem       Date:  2001-07-01       Impact factor: 6.986

4.  Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process.

Authors:  H Zhang; R J Pomerantz; G Dornadula; Y Sun
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  Cellular and viral specificities of human immunodeficiency virus type 1 vif protein.

Authors:  N Madani; D Kabat
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

6.  Improvement of an in-gel tryptic digestion method for matrix-assisted laser desorption/ionization-time of flight mass spectrometry peptide mapping by use of volatile solubilizing agents.

Authors:  V Soskic; J Godovac-Zimmermann
Journal:  Proteomics       Date:  2001-11       Impact factor: 3.984

7.  The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle.

Authors:  S Yang; Y Sun; H Zhang
Journal:  J Biol Chem       Date:  2000-11-08       Impact factor: 5.157

8.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.

Authors:  Ann M Sheehy; Nathan C Gaddis; Jonathan D Choi; Michael H Malim
Journal:  Nature       Date:  2002-07-14       Impact factor: 49.962

9.  Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.

Authors:  Kate N Bishop; Rebecca K Holmes; Michael H Malim
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

10.  MAGI-1c: a synaptic MAGUK interacting with muSK at the vertebrate neuromuscular junction.

Authors:  L Strochlic; A Cartaud; V Labas; W Hoch; J Rossier; J Cartaud
Journal:  J Cell Biol       Date:  2001-05-28       Impact factor: 10.539

View more
  28 in total

Review 1.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

2.  HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.

Authors:  Iris Cadima-Couto; Nuno Saraiva; Ana Catarina C Santos; Joao Goncalves
Journal:  J Neuroimmune Pharmacol       Date:  2011-01-29       Impact factor: 4.147

3.  Molecular insight into the conformational dynamics of the Elongin BC complex and its interaction with HIV-1 Vif.

Authors:  Sean R Marcsisin; John R Engen
Journal:  J Mol Biol       Date:  2010-08-20       Impact factor: 5.469

Review 4.  Advances in the structural understanding of Vif proteins.

Authors:  Pierre Barraud; Jean-Christophe Paillart; Roland Marquet; Carine Tisné
Journal:  Curr HIV Res       Date:  2008-03       Impact factor: 1.581

5.  Hydrodynamic and functional analysis of HIV-1 Vif oligomerization.

Authors:  Stephen M Techtmann; Rodolfo Ghirlando; Sandra Kao; Klaus Strebel; Ernest L Maynard
Journal:  Biochemistry       Date:  2012-03-05       Impact factor: 3.162

6.  Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.

Authors:  Tao Zuo; Donglai Liu; Wei Lv; Xiaodan Wang; Jiawen Wang; Mingyu Lv; Wenlin Huang; Jiaxin Wu; Haihong Zhang; Hongwei Jin; Liangren Zhang; Wei Kong; Xianghui Yu
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 7.  Structural insights for HIV-1 therapeutic strategies targeting Vif.

Authors:  Jason D Salter; Guillermo A Morales; Harold C Smith
Journal:  Trends Biochem Sci       Date:  2014-08-12       Impact factor: 13.807

8.  Characterization of RNA binding and chaperoning activities of HIV-1 Vif protein. Importance of the C-terminal unstructured tail.

Authors:  Dona Sleiman; Serena Bernacchi; Santiago Xavier Guerrero; Franck Brachet; Valéry Larue; Jean-Christophe Paillart; Carine Tisne
Journal:  RNA Biol       Date:  2014-07-22       Impact factor: 4.652

9.  Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.

Authors:  Zeli Zhang; Qinyong Gu; Ananda Ayyappan Jaguva Vasudevan; Manimehalai Jeyaraj; Stanislaw Schmidt; Jörg Zielonka; Mario Perković; Jens-Ove Heckel; Klaus Cichutek; Dieter Häussinger; Sander H J Smits; Carsten Münk
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

Review 10.  Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.

Authors:  Jessica L Smith; Wei Bu; Ryan C Burdick; Vinay K Pathak
Journal:  Trends Pharmacol Sci       Date:  2009-12       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.